{"entity": "researcher", "timestamp": "2026-07-22T17:43:49.114Z", "family": "Barrag\u00e1n", "given": "Isabel", "initials": "I", "orcid": "0000-0002-8586-6502", "affiliations": ["Medical Oncology Service (Group of Translational Research in Cancer Immunotherapy), Regional and Virgen de la Victoria University Hospitals, Institute of Biomedical Research in Malaga and BIONAND Nanomedicine Platform (IBIMA BIONAND Platform), C/Marqu\u00e9s de Beccar\u00eda n\u00b03, 29010 M\u00e1laga, Spain.", "Group of Pharmacoepigenetics, Department of Physiology and Pharmacology, Karolinska Institutet, 171 77 Stockholm, Sweden."], "links": {"self": {"href": "https://publications.scilifelab.se/researcher/b21619a3feff43a2bc28b5834c825d0c.json"}, "display": {"href": "https://publications.scilifelab.se/researcher/b21619a3feff43a2bc28b5834c825d0c"}}, "publications": [{"entity": "publication", "iuid": "4036ea5cd46541d3aa846db00de8ef08", "links": {"self": {"href": "https://publications.scilifelab.se/publication/4036ea5cd46541d3aa846db00de8ef08.json"}, "display": {"href": "https://publications.scilifelab.se/publication/4036ea5cd46541d3aa846db00de8ef08"}}, "title": "Fluorometric Quantification of Total Cell-Free DNA as a Prognostic Biomarker in Non-Small-Cell Lung Cancer Patients Treated with Immune Checkpoint Blockade.", "authors": [{"family": "Oliver", "given": "Javier", "initials": "J", "orcid": "0000-0002-8073-4711", "researcher": {"href": "https://publications.scilifelab.se/researcher/097176806fcd49a996f7e153d99f5640.json"}}, {"family": "Onieva", "given": "Juan Luis", "initials": "JL", "orcid": "0000-0001-8976-8099", "researcher": {"href": "https://publications.scilifelab.se/researcher/64f312743c45466297c164d9074855cc.json"}}, {"family": "Garrido-Barros", "given": "Mar\u00eda", "initials": "M"}, {"family": "Cobo-Dols", "given": "Manuel", "initials": "M", "orcid": "0000-0003-3402-1144", "researcher": {"href": "https://publications.scilifelab.se/researcher/1073676fec6f45e09cf82b9496b123bd.json"}}, {"family": "Mart\u00ednez-G\u00e1lvez", "given": "Beatriz", "initials": "B"}, {"family": "Garc\u00eda-Pel\u00edcano", "given": "Ana Isabel", "initials": "AI"}, {"family": "Dubbelman", "given": "Jaime", "initials": "J"}, {"family": "Ben\u00edtez", "given": "Jos\u00e9 Carlos", "initials": "JC", "orcid": "0000-0002-8776-9132", "researcher": {"href": "https://publications.scilifelab.se/researcher/b306b1d50c0b4c4390c1ad28eba47120.json"}}, {"family": "Mart\u00edn", "given": "Juan Zafra", "initials": "JZ", "orcid": "0000-0003-4778-4271", "researcher": {"href": "https://publications.scilifelab.se/researcher/4c7177932eed44bda5145cc1d5ea3245.json"}}, {"family": "Cantero", "given": "Alejandra", "initials": "A"}, {"family": "P\u00e9rez-Ruiz", "given": "Elisabeth", "initials": "E", "orcid": "0000-0001-7204-0800", "researcher": {"href": "https://publications.scilifelab.se/researcher/ea96e2b1045d4b338bf7e4055630af74.json"}}, {"family": "Rueda-Dom\u00ednguez", "given": "Antonio", "initials": "A", "orcid": "0000-0001-5890-0149", "researcher": {"href": "https://publications.scilifelab.se/researcher/6fe1b9aa037c4ded9bcf9d1f10337899.json"}}, {"family": "Barrag\u00e1n", "given": "Isabel", "initials": "I", "orcid": "0000-0002-8586-6502", "researcher": {"href": "https://publications.scilifelab.se/researcher/b21619a3feff43a2bc28b5834c825d0c.json"}}], "type": "journal article", "published": "2023-06-26", "journal": {"title": "Cancers (Basel)", "issn": "2072-6694", "volume": "15", "issue": "13", "issn-l": "2072-6694"}, "abstract": "The present study aimed to investigate the potential of basal cell-free fluorometric DNA (cfDNA) quantification as a prognostic biomarker in advanced non-small cell lung cancer (NSCLC) patients treated with an Immune Checkpoint Blockade (ICB). A discovery and validation cohort of 61 and 31 advanced lung cancer patients treated with ICB were included in this study. Quantification of cfDNA concentration was performed before the start of the treatment and patients were followed up for a median of 34 (30-40) months. The prognostic predicted value of cfDNA was evaluated based on ROC, and Cox regression was conducted via univariate and multivariate analyses to estimate the hazard ratio. We observed that a cfDNA cut-off of 0.55 ng/\u00b5L before the ICB determines the overall survival of patients with a log rank p-value of 3.3 \u00d7 10-4. That represents median survivals of 3.8 vs. 17.5 months. Similar results were obtained in the validation cohort being the log rank p-value 3.8 \u00d7 10-2 with median survivals of 5.9 vs. 24.3. The univariate and multivariate analysis revealed that the cut-off of 0.55 ng/\u00b5L before ICB treatment was an independent predictive factor and was significantly associated with a better survival outcome. High cfDNA concentrations identify patients with advanced NSCLC who do not benefit from the ICB. The determination of cfDNA is a simple test that could select a group of patients in whom new therapeutic strategies are needed.", "doi": "10.3390/cancers15133357", "pmid": "37444467", "labels": {"Bioinformatics Support for Computational Resources": "Service"}, "xrefs": [{"db": "pmc", "key": "PMC10341133"}, {"db": "pii", "key": "cancers15133357"}], "notes": [], "created": "2023-11-27T22:02:11.176Z", "modified": "2024-01-16T13:48:33.106Z"}, {"entity": "publication", "iuid": "c6aa9463b9d146c5b285245971ccfc44", "links": {"self": {"href": "https://publications.scilifelab.se/publication/c6aa9463b9d146c5b285245971ccfc44.json"}, "display": {"href": "https://publications.scilifelab.se/publication/c6aa9463b9d146c5b285245971ccfc44"}}, "title": "Treatment of Metastatic Melanoma at First Diagnosis: Review of the Literature.", "authors": [{"family": "Berciano-Guerrero", "given": "Miguel-Angel", "initials": "MA", "orcid": "0000-0002-5437-5196", "researcher": {"href": "https://publications.scilifelab.se/researcher/4d4dad0bbcc6438982dea3413268994e.json"}}, {"family": "Guardamagna", "given": "Mora", "initials": "M"}, {"family": "Perez-Ruiz", "given": "Elisabeth", "initials": "E", "orcid": "0000-0001-7204-0800", "researcher": {"href": "https://publications.scilifelab.se/researcher/ea96e2b1045d4b338bf7e4055630af74.json"}}, {"family": "Jurado", "given": "Jose-Miguel", "initials": "JM"}, {"family": "Barrag\u00e1n", "given": "Isabel", "initials": "I", "orcid": "0000-0002-8586-6502", "researcher": {"href": "https://publications.scilifelab.se/researcher/b21619a3feff43a2bc28b5834c825d0c.json"}}, {"family": "Rueda-Dominguez", "given": "Antonio", "initials": "A"}], "type": "journal article", "published": "2022-08-24", "journal": {"title": "Life (Basel)", "issn": "2075-1729", "volume": "12", "issue": "9", "issn-l": null}, "abstract": "Metastatic melanoma (MM) is a pathological entity with a very poor prognosis that, until a few decades ago, had a low response rate to systemic treatments. Fortunately, in the last few years, new therapies for metastatic melanoma have emerged. Currently, targeted therapy and immunotherapy are the mainstays of the therapeutic arsenal available for patients with unresectable or metastatic melanoma. However, both clinical evolution and drug efficacy in melanoma patients are very different depending on the stage at which it is diagnosed. In fact, the aggressiveness of melanoma is different depending on whether it debuts directly as metastatic disease or if what occurs is a relapse after a first diagnosis at an early stage, although the biological determinants are largely unknown. Another key aspect in the clinical management of metastatic melanoma at first diagnosis strives in the different prognosis of melanoma of unknown primary (MUP) compared to melanoma of known primary (MPK). Understanding the mechanisms behind this, and the repercussion of implementing targeted and immune therapies in this specific form is crucial for designing diagnosis and treatment decision algorithms that optimize the current strategies. In this review article, we recapitulate the information available thus far regarding the epidemiology and response to immunotherapy treatments or targeted therapy in patients diagnosed with metastatic melanoma as a first diagnosis, with especial emphasis on the emerging specific information of the subpopulation formed by MUP patients.", "doi": "10.3390/life12091302", "pmid": "36143339", "labels": {"Bioinformatics Support for Computational Resources": "Service"}, "xrefs": [{"db": "pmc", "key": "PMC9505710"}, {"db": "pii", "key": "life12091302"}], "notes": [], "created": "2023-11-27T22:02:22.486Z", "modified": "2024-01-16T13:48:35.104Z"}]}